Essential Premium

Biotech IPO Fever Shows No Signs of Breaking

Deep Track and Cormorant are among the healthcare-focused investors backing three of the five biopharma companies slated to go public this week.

Greenlight Gains 5 Percent in July, But Clues to Rally Remain Scarce

David Einhorn’s hedge fund outperformed in a down month for many indices, but its top disclosed holdings offer few explanations for the gains.

Sponsored

Rethinking Equity Allocation From a Global Perspective

Hedge Funds Back Record Number of Billion-Dollar VC Funding Rounds

Coatue, Tiger Global, D.E. Shaw Ventures, and others are backing some of the year's largest private-company financings.

Related Content

AI Meets Biotech — and Hedge Funds Are Buying In

Stephen Taub

The Rich List: Institutional Investor’s 25th Annual Ranking of the Highest-Earning Hedge Fund Managers

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram